

Supplementary Table 1, Two-by-two table used for the calculation of reporting odds ratios (ROR).

	with an adverse event of interest	without an adverse event of interest
target drugs	n11	n12
other drugs	n21	n22

$$\text{ROR} = (n11/n21)/(n12/n22)$$

Supplementary Table 2, Association Suspected drug (drug A) and the occurrence of aortic dissection in JADER

Drug A	Cases without drug A, n (%)	Cases with drug A, n (%)	Odds ratio (95%CI)
Alteplase (genetic recombination)	116/274147 (0.0423)	15/1042 (1.44)	34.0 (19.8-58.5)
Erythromycin ethyl succinic acid ester	128/274982 (0.0465)	3/207 (1.45)	31.1 (9.83-98.6)
Cyanocobalamin	126/274705 (0.0459)	5/484 (1.03)	22.5 (9.17-55.3)
Pranoprofen	128/274875 (0.0466)	3/314 (0.955)	20.5 (6.50-64.8)
mirabegron	128/274872 (0.0466)	3/317 (0.946)	20.3 (6.43-64.2)
Pazopanib hydrochloride	128/274821 (0.0466)	3/368 (0.815)	17.5 (5.55-55.2)
Budesonide formoterol fumarate hydrate	128/274797 (0.0466)	3/392 (0.765)	16.4 (5.21-51.8)
Edaravone	124/273642 (0.0453)	7/1547 (0.453)	9.99 (4.66-21.4)
Sunitinib malate	120/272689 (0.0440)	11/2620 (0.420)	9.54 (5.14-17.7)
Darbepoetin alfa (genetic recombination)	128/274462 (0.0466)	3/727 (0.413)	8.85 (2.81-27.9)
Atenolol	124/273181 (0.0454)	7/2008 (0.349)	7.68 (3.58-16.5)
Bevacizumab (genetic recombination)	113/269038 (0.0420)	18/6151 (0.293)	6.97 (4.23-11.5)
Doxazosin mesilate	123/272603 (0.0451)	8/2586 (0.309)	6.86 (3.35-14.0)
Concentrated glycerin·fructose	127/273929 (0.0463)	4/1260 (0.318)	6.85 (2.53-18.6)
Pentazocine	128/274210 (0.0467)	3/979 (0.306)	6.56 (2.09-20.7)
Hydroxyzine hydrochloride	128/274007 (0.0467)	3/1182 (0.254)	5.43 (1.73-17.1)
Urea	128/273968 (0.0467)	3/1221 (0.246)	5.26 (1.67-16.6)
Valsartan	114/267398 (0.0426)	17/7791 (0.218)	5.12 (3.07-8.52)
Epirubicin hydrochloride	128/273876 (0.0467)	3/1313 (0.229)	4.89 (1.55-15.4)
Montelukast sodium	128/273853 (0.0467)	3/1336 (0.225)	4.80 (1.53-15.1)
Amlodipine besylate	97/256239 (0.0379)	34/18950 (0.179)	4.74 (3.21-7.01)
Diltiazem hydrochloride	126/272889 (0.0462)	5/2300 (0.217)	4.71 (1.92-11.5)
Benidipine hydrochloride	126/272737 (0.0462)	5/2452 (0.204)	4.41 (1.80-10.8)
Palonosetron hydrochloride	128/273703 (0.0468)	3/1486 (0.202)	4.32 (1.37-13.6)
Sorafenib tosylate	123/270850 (0.0454)	8/4339 (0.184)	4.06 (1.98-8.31)
Tocilizumab (genetic recombination)	126/272521 (0.0462)	5/2668 (0.187)	4.05 (1.66-9.92)
Paclitaxel	124/270904 (0.0458)	7/4285 (0.163)	3.57 (1.67-7.65)
Nifedipine	120/268011 (0.0448)	11/7178 (0.153)	3.42 (1.85-6.35)
Bisoprolol fumarate	127/272636 (0.0466)	4/2553 (0.157)	3.36 (1.24-9.11)
Fentanyl	128/273230 (0.0468)	3/1959 (0.153)	3.27 (1.04-10.3)
Trichlormethiazide	128/273218 (0.0468)	3/1971 (0.152)	3.25 (1.03-10.2)
maintenance solution	128/273177 (0.0469)	3/2012 (0.149)	3.18 (1.01-10.0)
Rosuvastatin calcium	125/271092 (0.0461)	6/4097 (0.146)	3.18 (1.40-7.21)
Carvedilol	123/269569 (0.0456)	8/5620 (0.142)	3.12 (1.53-6.38)
Pravastatin sodium	125/270754 (0.0462)	6/4435 (0.135)	2.93 (1.29-6.65)
Olmesartan medoxomil	125/270628 (0.0462)	6/4561 (0.132)	2.85 (1.25-6.46)
Capecitabine	127/272156 (0.0467)	4/3033 (0.132)	2.83 (1.04-7.65)
Heparin sodium	126/271177 (0.0465)	5/4012 (0.125)	2.68 (1.10-6.56)
Alfacalcidol	123/268553 (0.0458)	8/6636 (0.121)	2.63 (1.29-5.38)
Celecoxib	126/271066 (0.0465)	5/4123 (0.121)	2.61 (1.07-6.38)
Folic acid	126/270840 (0.0465)	5/4349 (0.115)	2.47 (1.01-6.04)
prednisone	103/247717 (0.0416)	28/27472 (0.102)	2.45 (1.61-3.72)
Allopurinol	120/264162 (0.0454)	11/11027 (0.100)	2.20 (1.18-4.07)
Lansoprazole	115/258065 (0.0446)	16/17124 (0.0934)	2.10 (1.24-3.54)

These 44 drugs were listed as candidate drugs for aortic dissection, for which at least 3 cases were reported with a lower limit of the 95% confidence interval of the reporting odds ratio (ROR) of greater than 1.